Downloadable Publications
Discover the most recent information about Waldenstrom’s macroglobulinemia with IWMF Booklets, Treatment Guides, and Fact Sheets written by the IWMF, its affiliates, medical advisors, and IWMF-funded researchers. These publications are downloadable and most are available in several languages.
All languages
By Guy Sherwood, M.D., 2014.
Revised by Linda Nelson, 2018.
A comprehensive review of immunology and genetics as it relates to WM.
Written & compiled by Debra Entin, Glenn Cantor, Linda Nelson, Tom Hoffmann, & Sue Herms, 2022.
This booklet is designed to help patients with WM understand the basic functions of the bone marrow and how those are affected by our disease, including the bone marrow biopsy procedure and medical tests.
Written by Stephen M. Ansell, M.D., Ph.D, Carl Harrington, Steven Treon, M.D., Ph.D., 2023.
Essential Information: A Patient’s Guide on Waldenstrom’s Macroglobulinemia.
Written by Shayna Sarosiek, M.D., and Jorge J. Castillo, M.D., 2023.
Essential Information: A Physician’s Guide on Waldenstrom’s Macroglobulinemia.
Written by Shayna Sarosiek, M.D., Catherine A. Flynn, NP., and Jorge J. Castillo, M.D., 2023.
Essential Information: A Nurse’s Guide on Waldenstrom’s Macroglobulinemia.
By Peter DeNardis, Marcia Klepac, Elena Malunis, and Linda Nelson, 2017.
Revised by Linda Nelson, 2019.
Revised by Linda Nelson, Sue Herms, Carl Harrington, 2024.
This booklet answers frequently asked questions about WM in a very readable format for those who may not have a strong background in biology.
Written & compiled by Guy Sherwood, M.D., Bret Blakeslee, Sue Herms, & Peter DeNardis, 2015.
Revised by Linda Nelson, Glenn Cantor, & Sue Herms, 2023.
This glossary is designed to help patients with WM learn and understand pertinent medical terms that relate to the disease.
By Guy Sherwood, M.D., 2007
Revised by Linda Nelson and Sue Herms, 2016, 2020, 2023.
A reference booklet of medical terms and tests, this revision places particular emphasis on expanding the explanation of the Complete Blood Count and on Immunoglobulins. Tests for beta-2 microglobulin and light chains have been added, as has genetics testing.
Designed to provide detailed answers to questions about Waldenstrom’s macroglobulinemia, including a full glossary of terms.
By Dipti Talaulikar, M.D., Constantine Tam, M.D., et al, 2022.
This booklet is a consensus established by the Australian Medical Scientific Advisory Group, which consists of a panel of haematologists across Australia, and it is provided by the IWMF Affiliate (WMozzies) in Australia.
By Christian Buske, M.D., and George Hess, M.D., 2014.
Revised 2019.
This booklet is provided by the IWMF-Affiliate Morbus Waldenstrom (MOWA) in Germany.
By Shirley D’Sa, M.D., 2014, updated 2018, updated 2020.
This booklet is provided by the IWMF Affiliate Waldenstrom’s UK (WMUK). The drugs mentioned in the booklet are noted by their generic names and by their UK-specific trade names and may/may not be available in UK/US (or elsewhere) unless in the context of a clinical trial.
All languages
These Treatment Options Guides review drug therapies and treatment guidelines currently used in the management of Waldenstrom’s macroglobulinemia. They are designed to provide patients with some of the necessary information to allow them to participate with their physicians in determining the best course of treatment for their disease.
By Suzanne Herms, 2016
Revised 2021
This Guide discusses alkylating agents, such as chlorambucil (Leukeran), cyclophosphamide (Cytoxan), melphalan (Alkeran) and bendamustine (Bendeka, Treanda, Levact), as well as nucleoside analogs, such as fludarabine (Fludara) and cladribine (2CdA or Leustatin).
By Suzanne Herms, 2016
Revised 2021
This Guide discusses monoclonal antibodies, such as rituximab (Rituxan or Mabthera), ofatumumab (Arzerra), and alemtuzumab (Campath).
By Suzanne Herms, 2016
Revised 2021
This Guide includes proteasome inhibitors, such as bortezomib (Velcade), carfilzomib (Kyprolis), and ixazomib (Ninlaro).
By Suzanne Herms, 2016
Revised 2021
This Guide discusses targeted therapies/pathway inhibitors to B-cell signaling, such as ibrutinib (Imbruvica) and everolimus (RAD001 or Afinitor).
All languages
These are short summaries that include information about WM, common treatments, and other associated topics.